Hiru Corporation

Hiru Corporation

February 09, 2011 13:00 ET

MindUp BioResearch (HIRU) Participates in the Fourth Conference of the Translational Cancer Medicine 2010 (USA), San Francisco, California

BELGRADE, SERBIA--(Marketwire - Feb. 9, 2011) - Hiru Corporation (PINK SHEETS:HIRU) (http://www.hirucorporation.com/), is pleased to announce that researchers from its MindUp BioResearch (www.mindupbioresearch.com), European subsidiary have presented their results at the fourth Conference of the Translational Cancer Medicine 2010 (USA), held in San Francisco, California, July 11-14, 2010, under the auspices of American Association for Cancer Research (AACR). The AACR (http://www.aacr.org) is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Dr Sabera Ruzdijic, the Leader of MindUp Bioresearch Group said: "Translational research is a key programmatic priority of the American Association for Cancer Research, and this fourth conference in the Translational Cancer Medicine Conference Series was developed with this in mind. This international conference was an excellent opportunity to get insight into the current advances in translational cancer medicine, and new collaborations were fostered through the open discourse essential for progress against cancer. We were pleased that we were able to present our latest results on investigation of genomic basis of glioblastoma development, the most frequent and the most aggressive human brain tumors. We observed that p53 gene alteration could be an early event in tumor development, while PTEN gene inactivation and EGFR gene amplification may lead to tumor progression and therefore indicate a subgroup of patients with more aggressive disease. These results confirm the important role of these genes in development and predicting of this severe disease in central nervous system. Dr Jasna Bankovic, as a presenting author, had a long discussion with the visitors of our poster presentation answering all the questions on the topic presented." 

Dr Sabera Ruzdijic added: "Translational cancer medicine takes place at the interface between the lab and the clinic. It transitions basic science breakthroughs to the practice of medicine and uses clinical outcome to feed back into basic research. Consecutively, to make any advances in translational cancer medicine, there must be open lines of communication between researchers and clinicians."

At the company website http://www.hirucorporation.com/ you can find the poster presented at the Conference.

The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf of Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contact Information